Premium
Prolifertive effect of 17beta‐trenbolone on human prostate cancer cell line
Author(s) -
Lee HeeSeok,
Park EunJung,
Han Songyi,
Oh GyeongYong,
Kim MinHee,
Lee KwangSoo,
Moon Guiim,
Hwang MyungSil,
Hwang InGyun
Publication year - 2015
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.29.1_supplement.752.2
Subject(s) - prostate cancer , cancer cell lines , cancer research , medicine , oncology , cancer , chemistry , cancer cell
Trenbolone acetate (TBA) is synthetic anabolic steroid which have used in speed muscle development in cattle. Some of TBA are converted into 17beta‐trenbolone (17TB, 17b‐hydroxy‐estra‐4,9,11‐trien‐3‐one), which exerts androgenic activity by binding with androgen receptor like testosterone and dihydrotestosterone (DHT). It has been reported that cross‐talk between androgen and cell cycle regulator modulates prostate cancer cell progression. Since 17TB exhibits androgenic activity like DHT, it is important for knowing role of 17TB on prostate cancer cell progression. In this study, we found that 17TB induced prostate cancer cell proliferation with concentration dependent manner (EC50=0.03nM). Furthermore, cell growth by 17TB was completely inhibited in presence of 17TB and 10μM bicalutamide, which acts as an androgen receptor antagonist. To investigate the molecular mechanism of 17TB on prostate cancer cells, western blot analysis was performed. Indeed, 17TB increased cell cycle regulatory proteins cyclin A, cyclin B, cyclin D and it similar with DHT treatment. These data suggest that 17TB promotes 22Rv1 androgen‐dependent prostate cancer cell proliferation via regulation of cell cycle.